Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | PTPRC | P08575 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | CA6 | P23280 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | TTR | P02766 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3203499 | 0.87 | ACE2 (0.51) | ACE2GRM1TDP1KMT2AMEN1 | |
| SCHEMBL30848060 | 0.85 | ACE2 (0.46) | ACE2GRM1TDP1KMT2AMEN1 | |
| SCHEMBL29171910 | 0.85 | ACE2 (0.46) | ACE2GRM1TDP1KMT2AMEN1 | |
| SCHEMBL7768437 | 0.82 | ACE2 (0.50) | ACE2GRM1TDP1KMT2AMEN1 | |
| SCHEMBL3893604 | 0.81 | PTPRC (0.43) | ACE2GRM1TDP1KMT2AMEN1 | |
| SCHEMBL2312050 | 0.81 | HTT (0.41) | ACE2GRM1TDP1KMT2AMEN1 | |
| SCHEMBL15877839 | 0.81 | NOTUM (0.50) | TDP1KMT2AMEN1HTTHPGD | |
| SCHEMBL4577143 | 0.79 | ACE2 (0.56) | ACE2GRM1TDP1KMT2AMEN1 | |
| SCHEMBL9068206 | 0.79 | KDM4E (0.55) | ACE2GRM1TDP1KMT2AMEN1 | |
| SCHEMBL31401118 | 0.79 | GRM1 (0.50) | ACE2GRM1TDP1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999758-B2 | Inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of cancer | INVENTIVA (FR) | 2024-06-04 | — | — | US | disclosed |
| CN-113039182-B | Inhibitors of YAP/TAZ-TEAD interactions and their use in cancer treatment | 伊文蒂瓦公司 | 2024-02-20 | — | — | CN | disclosed |
| US-20230058729-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2023-02-23 | — | — | US | disclosed |
| EP-3860990-B1 | INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER | INVENTIVA (FR) | 2022-09-14 | — | — | EP | disclosed |
| US-20210323982-A1 | INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER | INVENTIVA (FR) | 2021-10-21 | — | — | US | disclosed |
| US-11136327-B2 | Macrocycles as factor XIA inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-10-05 | — | — | US | disclosed |
| EP-3860990-A1 | INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER | Inventiva (FR) | 2021-08-11 | — | — | EP | disclosed |
| CN-113039182-A | Inhibitors of YAP/TAZ-TEAD interaction and their use in cancer treatment | 伊文蒂瓦公司 | 2021-06-25 | — | — | CN | disclosed |
| EP-3786165-A1 | SYNTHETIC INTERMEDIATES FOR PRODUCING MACROCYCLES AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2021-03-03 | — | — | EP | disclosed |
| EP-2534154-B1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-05 | — | — | EP | disclosed |
| EP-3632908-A1 | INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER | Inventiva (FR) | 2020-04-08 | — | — | EP | disclosed |
| EP-3632908-A1 | INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER | Inventiva (FR) | 2020-04-08 | — | — | EP | disclosed |
| US-20200087312-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB (US) | 2020-03-19 | — | — | US | disclosed |
| US-20180022753-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-01-25 | — | — | US | disclosed |
| US-9802939-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-31 | — | — | US | disclosed |
| US-20150112058-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-04-23 | — | — | US | disclosed |
| US-8940720-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2534154-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120041190-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-16 | — | — | US | disclosed |
| WO-2011100401-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150112058-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | ACE2 176/4885GRM1 4668/4885TDP1 2393/4885 |
| US-20120041190-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | ACE2 176/4885GRM1 4668/4885TDP1 2393/4885 |
| US-20200087312-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | ACE2 176/4885GRM1 4668/4885TDP1 2393/4885 |
| US-20210323982-A1 | INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER | YAP1, TEAD2, YES1 | ACE2 3139/4885GRM1 4125/4885TDP1 1174/4885 |
| US-11999758-B2 | Inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of cancer | YAP1, TEAD2, YES1 | ACE2 3139/4885GRM1 4125/4885TDP1 1174/4885 |
| US-11136327-B2 | Macrocycles as factor XIA inhibitors | TFPI, TFPI2, F11 | ACE2 176/4885GRM1 4668/4885TDP1 2393/4885 |
| US-20180022753-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | ACE2 176/4885GRM1 4668/4885TDP1 2393/4885 |
| US-20230058729-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | ACE2 176/4885GRM1 4668/4885TDP1 2393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.